Skip to main content

Adaptive Biotechnologies Corporation Value Stock - Dividend - Research Selection

Adaptive Biotechnologies Corporation

ISIN: US00650F1093, WKN: A2PLR5

Market price date: 25.09.2020
Market price: 48,29 USD




Adaptive Biotechnologies Corporation Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-09-2020
Cash flow
Net operating cash flow 205.404.000
Capital Expenditures -11.200.000
Free cash flow 194.204.000
Balance sheet
Total Equity 571.039.000
Liabilities & Shareholders equity 912.302.000
Income statement
Net income -68.606.000
Eps (diluted) -0,790
Diluted shares outstanding 86.843.000
Net sales/revenue 85.071.000

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C 20,42
   
P/FC 21,59
Balance sheet
ROI-7,52
ROE62,59
Income statement
P/E-61,13
Div. Yield0,00%
P/B7,34
P/S49,30


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolADPT
Market Capitalization4.193.648.384,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceIFRS in Millionen USD
Stock Split
Internethttp://www.adaptivebiotech.com


Description of the company

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.adaptivebiotech.com